Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.39 |
| ▸ | CES2 | O00748 | 2/20 | 0.38 |
| ▸ | CES1 | P23141 | 2/20 | 0.38 |
| ▸ | NAAA | Q02083 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.36 |
| ▸ | EBP | Q15125 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29211131 | 0.81 | CHRM2 (0.46) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL31314899 | 0.81 | CHRM2 (0.46) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL29211095 | 0.79 | CHRM2 (0.46) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL5046411 | 0.77 | GAA (0.43) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL3409880 | 0.77 | GAA (0.43) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL29211091 | 0.75 | CHRM2 (0.46) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL28315620 | 0.72 | GAA (0.44) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL28315934 | 0.72 | GAA (0.44) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL28314369 | 0.72 | GAA (0.44) | GAASCN5ASCN9ACES2CES1 | |
| SCHEMBL28315811 | 0.72 | GAA (0.44) | GAASCN5ASCN9ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5288503-A | WATER-PERMEABLE DIFFUSION BARRIER OF POLYVINYL ALCOHOL | SRCHEM INCORPORATED (US) | 1994-02-22 | — | — | US | claimed |
| US-5260066-A | Cryogel bandage containing therapeutic agent | SRCHEM INCORPORATED (US) | 1993-11-09 | — | — | US | claimed |
| EP-3185850-B1 | SKIN COLOR-IMPROVING AGENT AND COMPOSITION FOR IMPROVING SKIN COLOR | SHOWA DENKO KK (JP) | 2019-10-09 | — | — | EP | disclosed |
| US-20170312301-A1 | SKIN BARRIER FUNCTION-IMPROVING AGENT AND COMPOSITION FOR IMPROVING SKIN BARRIER FUNCTION | SHOWA DENKO K.K. (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170312207-A1 | MOISTURIZING AGENT | SHOWA DENKO K.K. (JP) | 2017-11-02 | — | — | US | disclosed |
| US-20170312200-A1 | AN AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION | SHOWA DENKO K.K. (JP) | 2017-11-02 | — | — | US | disclosed |
| EP-3219304-A1 | MOISTURIZING AGENT | Showa Denko K.K. (JP) | 2017-09-20 | — | — | EP | disclosed |
| EP-3213753-A1 | SKIN BARRIER FUNCTION-IMPROVING AGENT AND COMPOSITION FOR IMPROVING SKIN BARRIER FUNCTION | Showa Denko K.K. (JP) | 2017-09-06 | — | — | EP | disclosed |
| EP-3213739-A1 | AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION AND ANTI-AGING COMPOSITION | Showa Denko K.K. (JP) | 2017-09-06 | — | — | EP | disclosed |
| CN-107106586-A | Skin barrier function improver and skin barrier function improvement composition | 昭和电工株式会社 | 2017-08-29 | — | — | CN | disclosed |
| CN-107106430-A | Mitochondrial function improver and aging prevent from using composition | 昭和电工株式会社 | 2017-08-29 | — | — | CN | disclosed |
| EP-0253901-B1 | SUSTAINED-RELEASE PREPARATION | TEIJIN LIMITED (JP) | 1991-12-27 | — | — | EP | disclosed |
| EP-0227836-B1 | SUSTAINED RELEASING PATCH | TEIJIN LIMITED (JP) | 1991-12-27 | — | — | EP | disclosed |
| US-4990340-A | Percutaneous administration without skin irritability | TEIJIN LIMITED (JP) | 1991-02-05 | — | — | US | disclosed |
| US-4801458-A | POROUS HOLLOW FIBERS FILLED WITH MEDICINE | TEIJIN LIMITED (JP) | 1989-01-31 | — | — | US | disclosed |
| EP-0179277-B1 | MEDICAL COMPOSITION FOR EXTERNAL APPLICATION | Kao Corporation (JP) | 1988-11-02 | — | — | EP | disclosed |
| EP-0253901-A1 | SUSTAINED-RELEASE PREPARATION | TEIJIN LIMITED (JP) | 1988-01-27 | — | — | EP | disclosed |
| US-4686211-A | Medical composition for external application | KAO CORPORATION (JP) | 1987-08-11 | — | — | US | disclosed |
| EP-0227836-A1 | SUSTAINED RELEASING PATCH | TEIJIN LIMITED (JP) | 1987-07-08 | — | — | EP | disclosed |
| EP-0179277-A1 | Medical composition for external application | Kao Corporation (JP) | 1986-04-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312200-A1 | AN AGENT FOR IMPROVING MITOCHONDRIAL FUNCTION | UQCRC1, ACAD9, CYP27B1 | GAA 3419/4885SCN5A 2993/4885SCN9A 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.